Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-06

Clinical Trial Update: Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of amrubicin in HER2-negative metastatic breast cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amrubicin (amrubicin)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-01-06